Needle Free Drug Delivery Devices Market Size, Share & Trends Report

Needle Free Drug Delivery Devices Market Size, Share & Trends Analysis Report By Technology, By Application (Vaccine Delivery, Pain Management, Insulin Delivery, Pediatric Injections), And Segment Forecasts, 2018 - 2024

  • Published Date: May, 2018
  • Base Year for Estimate: 2015
  • Report ID: 978-1-68038-879-4
  • Format: Electronic (PDF)
  • Historical Data: 2013 - 2015
  • Number of Pages: 90

Industry Insights

The global needle free drug delivery devices market size was valued at USD 6.72 billion in 2016. It is anticipated to register a CAGR of 10.2% over the forecast period. Growing incidence of transmission of infectious diseases such as AIDS, hepatitis viruses, dengue fever, and neurological disorders caused by West Nile Virus is one of the key trends stoking market growth.

U.S. needle free drug delivery devices market

The World Health Organization estimates showed that diseases transmitted through the use of injections have increased by 20.0% globally, thereby exhibiting clinical urgency to develop these devices. According to the organization, approximately 350 million people have been chronically infected by hepatitis B and prevalence of hepatitis B has increased lately owing to which, there are approximately 4 million cases of acute hepatitis B infection and 1 million deaths every year.

Moreover, surging demand for self-administration and pain-free drug delivery is one of the key growth stimulants of the market. Incorporation of these products is estimated to promote patient's self-dependency along with significant reduction in frequent hospital visits, thereby reducing hospital staff requirements and total treatment cost. 

Moreover, rapid technological advancements are paving way for these minimally invasive devices. Associated benefits of such advancements include slow and controlled flow of drug into the body as per patient’s needs, increased portability, and minimal skin damage. Growing awareness regarding the aforementioned benefits are projected to create an upswing in the demand for needle free drug delivery devices.

Technology Insights

On the basis of technology, the jet injectors segment was at the forefront of the market in 2016. This can be attributed to growing penetration of technologically advanced products in the market. A spray of powdered drug is administered through the surface of the skin with the help of a high-pressure jet, thus imparting benefits over conventional methods of drug delivery.

For instance, PharmaJet's product, PharmaJet Stratis delivers an influenza vaccine in 1/10th of a second. Major benefits associated with this technology include rapid administration, improved dosage accuracy, better diffusion into tissues, faster response rates, reduced pain, reduced sharps waste, and easy portability.

On the other hand, transdermal patches are likely to post a CAGR of over 10.0% owing to associated benefits such as direct delivery, ease of usage, painless, and rising prevalence of diabetes. Furthermore, technological advancements such as development of reservoir type patch technology, which provides patients with a reservoir of drug, enabling controlled dosage and frequency, are expected to spur the demand for these products over the forecast period.

Application Insights

The insulin delivery segment commanded over one third of the global needle free drug delivery devices market in 2015. As per a report published in NCBI, the success rate of first self-administration was 94.0% and of the second was 100% in diabetes without the requirement of any assistance by patients. In addition, self-administration associated with insulin delivery devices is supplementing the growth of the segment.

Global needle free drug delivery devices market

Moreover, availability of wide range of devices such as transdermal patches, jet injectors, and inhalers incorporated in the treatment of diabetes, contributed to the growth of the overall market during the forecast period. Increasing number of product approvals is projected to support the growth of the segment over the forecast period.

In January 2016, Sanofi and Mankind entered into a joint venture to develop an inhalable insulin drug named Afreeza. With the commercial availability of the product, the companies are poised to capture a larger share and further drive the market.

Regional Insights

North America held the largest revenue share of 41.0% in the global market in 2015. This can be attributed to high awareness among patient population regarding the availability of novel products and increasing R&D investments by prominent market players domiciled in this region. Presence of well-structured reimbursement framework is another major factor propelling the regional market. For instance, the revised Medicare and Medicaid policy provides reimbursement for medical supplies used in insulin delivery.

The Asia Pacific region holds significant growth potential. The region is expected to rise at a CAGR of over 12.0% during the forecast period. Widening base of patients is anticipated to augment the demand for needle free drug delivery devices. According to WHO, approximately 119 million people in South Asia are estimated to be affected by diabetes by 2030. Growing geriatric population, requiring home-based needle free drug delivery devices for enhanced mobility, and rising healthcare expenditure in emerging economies such as China and India are contributing to the growth of the market in APAC.

Needle Free Drug Delivery Devices Market Share Insights

Some of the key players in the market are Antares Pharma, Inc.; Injex Pharma AG; 3M; PharmaJet Inc.; Zogenix, Inc.; Bioject Medical Technologies, Inc.; Glide Pharmaceutical Technologies Ltd.; Penjet Corporation; Valeritas; D'Antonio Consultants International, Inc.; and Akra Dermojet. The industry rivalry is high and threat of new entrants is moderate owing to strong capital requirement for procuring technology and other intellectual properties from existing companies. The market players are resorting to sustainability strategies such as product launches, strategic collaborations, mergers & acquisitions, and technological innovations.

Moreover, rising number of raw material suppliers & distribution agreements initiated by these players for geographical expansion facilitate capture of a large market share. For instance, in May 2016, Inovio Pharmaceuticals, Inc. acquired BioJect in an attempt to increase its R&D efforts in novel vaccines and drug delivery devices area.

Report Scope



Base year for estimation


Actual estimates/Historical data

2013 - 2015

Forecast period

2016 - 2024

Market representation

Revenue in USD Million & CAGR from 2013 to 2024

Regional scope

North America, Europe, Asia Pacific, Latin America, MEA

Report coverage      

Revenue forecast, company share, competitive landscape, growth factors and trends

Country Scope

U.S., Canada, U.K., Germany, China, Japan, Mexico, Brazil, South Africa

15% free customization scope (equivalent to 5 analyst working days)

If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization

Segments Covered in the Report

This report forecasts revenue growth at global, regional & country levels and provides an analysis of the industry trends in each of the sub-segments from 2016 to 2024. For the purpose of this study, Grand View Research has segmented the global needle free drug delivery devices market report on the basis of technology, application, and region:

  • Technology Outlook (Revenue, USD Million, 2014 - 2024)

    • Jet injectors

    • Inhaler technology

    • Transdermal patch technology

    • Novel needle free technologies

  • Application Outlook (Revenue, USD Million, 2014 - 2024)

    • Vaccine delivery

    • Pain management

    • Insulin delivery for diabetes

    • Pediatric injections

    • Others

  • Regional Outlook (Revenue, USD Million, 2014 - 2024)

    • North America

      • U.S.

      • Canada

    • Europe

      • U.K.

      • Germany

    • Asia Pacific

      • Japan

      • China

      • India

    • Latin America

      • Mexico

      • Brazil

    • MEA

      • South Africa

Key questions answered by the report
Request for Customization

Choose License Type

Single User - $4,450
Multi User (2-5) - $6,450
Compass Access - $8,450

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • grand view research PCI DSS complaint grand view research paypal verified